Want to see KR:069620 full AI Analyst Report?
Daewoong Pharmaceutical Co., Ltd. (069620) Income Statement
Daewoong Pharmaceutical Co., Ltd. Income Statement
Last quarter (Q2 2026), Daewoong Pharmaceutical Co., Ltd.'s total revenue was $448.46B, an increase of 10.61% from the same quarter last year. In Q2, Daewoong Pharmaceutical Co., Ltd.'s net income was $33.37B. See Daewoong Pharmaceutical Co., Ltd.’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 1.57T | $ 1.42T | $ 1.38T | $ 1.28T | $ 1.15T | |
| $ 812.85B | $ 734.17B | $ 687.11B | $ 638.96B | $ 544.75B | |
| $ 617.34B | $ 586.23B | $ 565.57B | $ 543.16B | $ 455.84B | |
| Depreciation and Amortization | $ 50.27B | $ 48.98B | $ 43.80B | $ 39.69B | $ 40.88B |
| $ 245.78B | $ 112.52B | $ 164.91B | $ 86.80B | $ 129.61B | |
| $ 195.51B | $ 147.94B | $ 121.12B | $ 95.80B | $ 88.73B | |
| $ -3.67B | $ -91.39B | $ 881.52M | $ -57.47B | $ -68.97B | |
| $ 191.83B | $ 56.55B | $ 122.00B | $ 38.33B | $ 19.76B | |
| $ 195.86B | $ 24.73B | $ 121.74B | $ 42.24B | $ 24.51B | |
| Per Share Metrics | |||||
| Basic EPS | $ 17021.00 | $ 2149.85 | $ 10656.00 | $ 3815.95 | $ 2226.87 |
| Diluted EPS | $ 17021.00 | $ 2149.85 | $ 10656.00 | $ 3815.95 | $ 2226.87 |
| Weighted Average Shares Outstanding | 11.59M | 11.51M | 11.42M | 11.07M | 11.01M |
| Weighted Average Shares Outstanding (Diluted) | 11.59M | 11.51M | 11.42M | 11.07M | 11.01M |
Currency in KRW
